Rezdiffra (Resmetirom) South Asian Safety Profile Differences

Why South Asian Patients Require a Separate Clinical Lens

South Asian individuals develop metabolic-associated steatotic liver disease (MASLD) and its inflammatory form, MASH, at body weights well below the thresholds typically used to trigger screening in European-ancestry populations. This matters for resmetirom prescribing because the drug's approved dosing algorithm is weight-based, and South Asian patients may be undertreated at the 80 mg tier while carrying significant hepatic fibrosis.

A 2023 analysis published in Diabetes Care confirmed that South Asian adults in the UK Biobank developed type 2 diabetes a median of 10.5 years earlier than White European adults at equivalent BMI, with substantially higher visceral adiposity at BMI values considered "normal" by standard WHO thresholds 1. Liver fat accumulation follows the same pattern.

MASH Epidemiology in the South Asian Context

South Asian ancestry is an independent predictor of hepatic steatosis severity in multivariate analyses. The PNPLA3 rs738409 G allele, which confers roughly a 3.7-fold increase in steatohepatitis risk per allele, carries allele frequencies of approximately 0.26-0.31 in South Asian populations compared to 0.22-0.24 in European populations, based on gnomAD v3.1.2 population frequency data 2.

TM6SF2 rs58542926, a second major steatohepatitis locus, shows lower minor-allele frequency in South Asian individuals (roughly 0.05) than in Europeans (roughly 0.07), partially offsetting the PNPLA3 risk elevation. The net genetic burden, combined with environmental and dietary factors, still results in disproportionate MASH severity at lower BMI thresholds.

Cardiovascular Overlay

South Asian patients with MASH face a compounded cardiovascular risk that European-derived CV risk calculators systematically underestimate. The ACC/AHA 2019 guidelines note that South Asian ethnicity warrants a "risk-enhancing factor" designation that may prompt earlier statin initiation 3. Resmetirom's LDL-C-lowering effect (median reduction of approximately 13.6% at 100 mg in MAESTRO-NASH) may be clinically meaningful in this group, but statin co-prescription is common and introduces a drug-interaction signal discussed below.

MAESTRO-NASH Trial: What the Data Actually Show

The key MAESTRO-NASH trial (N=966), published in The New England Journal of Medicine in 2024, demonstrated that resmetirom 80 mg produced NASH resolution without worsening of fibrosis in 25.9% of patients versus 14.2% placebo (P<0.001), and resmetirom 100 mg achieved 29.9% versus 14.2% placebo (P<0.001) at 52 weeks 4.

Fibrosis improvement of at least one stage without worsening of NASH occurred in 24.2% (80 mg) and 25.9% (100 mg) versus 14.6% placebo 4.

Ethnicity Representation in MAESTRO-NASH

The MAESTRO-NASH publication and the FDA approval package do not report a specifically powered South Asian subgroup. The trial enrolled patients across North America and Europe, with Asian race reported as approximately 7% of the overall cohort. This category almost certainly conflates East Asian and South Asian participants, making ethnicity-specific effect estimates unreliable.

The FDA medical review for resmetirom (NDA 217785) notes that race-based subgroup analyses did not identify heterogeneity of treatment effect, but the confidence intervals for non-White subgroups are wide enough to preclude firm conclusions 5.

What Absence of Powered Data Means Clinically

No powered subgroup data does not mean no difference exists. It means the study was not designed to detect one. Given the pharmacogenomic factors detailed below, clinicians should not assume that the 25-30% NASH resolution rates observed in the overall trial apply equally to South Asian patients without stratification.

Resmetirom Pharmacogenomics in South Asian Populations

Resmetirom is predominantly metabolized by CYP2C8 and transported into hepatocytes by OATP1B1 (encoded by SLCO1B1) and OATP1B3 (encoded by SLCO1B3). Both pathways show clinically relevant genetic variation with differing allele frequencies across ancestry groups.

CYP2C8 Variation

CYP2C8 converts resmetirom to its primary inactive metabolites. The CYP2C8*3 allele (rs11572080, rs10509681) reduces enzyme activity and is present in approximately 0.4-0.7% minor allele frequency in South Asian populations versus 8-13% in European populations, per PharmGKB population data 6. Poor CYP2C8 metabolizers show higher plasma AUC for CYP2C8 substrates.

Paradoxically, the lower CYP2C83 frequency in South Asian patients suggests this allele is less likely to cause resmetirom overexposure in this group than in Europeans. However, CYP2C82 (rs11572103), more prevalent in African-ancestry individuals, also reduces activity and complicates pan-Asian generalization.

SLCO1B1 and Hepatic Uptake

SLCO1B1 c.521T>C (rs4149056), which encodes the OATP1B1 reduced-function variant, occurs in approximately 12-17% heterozygous frequency in South Asian populations. This variant is best known for increasing statin myopathy risk but also affects hepatic first-pass extraction of OATP1B1 substrates 7.

Resmetirom's hepatic accumulation depends on OATP1B1-mediated uptake. Reduced-function SLCO1B1 variants could theoretically decrease hepatic resmetirom concentrations while increasing plasma exposure, potentially altering both efficacy and peripheral side-effect burden. No published pharmacokinetic study has prospectively evaluated resmetirom AUC by SLCO1B1 genotype in South Asian participants. This gap is clinically significant.

Drug-Metabolizing Enzyme Inducers Common in South Asians

Several herbal preparations widely used in South Asian communities, including turmeric-derived curcumin at high doses and Ashwagandha (Withania somnifera), are CYP inducers or inhibitors in in-vitro models 8. Curcumin at supplemental doses (500-2000 mg/day) may induce CYP1A2 and CYP3A4 while inhibiting CYP2C8 at higher concentrations, though human pharmacokinetic data remain sparse. Clinicians prescribing resmetirom to South Asian patients should obtain a thorough herbal supplement history.

Safety Profile: Signals Clinicians Should Prioritize

Hepatotoxicity Monitoring

In MAESTRO-NASH, ALT elevations greater than 3x the upper limit of normal occurred in 4.5% (80 mg), 6.2% (100 mg), and 2.5% (placebo) of patients 4. The Rezdiffra prescribing information recommends checking ALT and AST at baseline, then at 3 months, then every 6 months thereafter 9.

South Asian patients with MASH often present with elevated ALT at baseline due to higher rates of concurrent type 2 diabetes and insulin resistance. Distinguishing drug-induced ALT elevation from disease progression may require more frequent monitoring intervals, particularly in the first 6 months.

Statin Interaction and Myopathy Risk

Resmetirom inhibits OATP1B1 and OATP1B3 transporters at clinically relevant concentrations, raising plasma statin AUC. The Rezdiffra label contraindicates concurrent use with rosuvastatin doses above 20 mg and simvastatin doses above 20 mg, and recommends limiting atorvastatin to 40 mg daily 9.

Given that ACC/AHA guidelines recommend earlier and more intensive statin therapy in South Asian patients, the proportion of this population on moderate-to-high-intensity statins is likely higher than in the MAESTRO-NASH cohort. A clinician prescribing resmetirom to a South Asian patient already on rosuvastatin 40 mg must reduce the statin dose before initiating resmetirom. Myalgia and creatine kinase elevation should be assessed at baseline and at each follow-up visit.

The clinical relevance compounds when SLCO1B1 rs4149056 is present: reduced OATP1B1 function already raises statin plasma levels, and resmetirom adds a second inhibitory layer on the same transporter 7.

Gallbladder and Biliary Events

Thyroid hormone receptor-beta agonism increases bile acid synthesis and biliary cholesterol secretion. In MAESTRO-NASH, cholelithiasis occurred in 2.7% (resmetirom combined) versus 1.6% placebo 4. South Asian populations carry higher background rates of cholelithiasis related to dietary patterns and genetic cholesterol metabolism differences. This additive risk warrants baseline abdominal ultrasound before resmetirom initiation and clinical vigilance for right upper quadrant symptoms during treatment.

Thyroid Function

Resmetirom selectively activates thyroid hormone receptor-beta in the liver, minimizing systemic thyroid effects, but TSH suppression was not zero in MAESTRO-NASH. TSH decreased a median of 7.7% from baseline at 100 mg 4. South Asian individuals have a higher prevalence of thyroid autoimmunity, particularly Hashimoto's thyroiditis, in some geographic cohorts 10. Baseline TSH and anti-TPO antibody testing before resmetirom initiation is reasonable practice in this population.

Dosing Considerations for South Asian Patients

The approved weight-based dosing threshold (80 mg if body weight <100 kg; 100 mg if ≥100 kg) was calibrated on a predominantly Western trial population. South Asian patients rarely exceed 100 kg yet may have severe hepatic fibrosis, high visceral adiposity, and substantial metabolic burden. Most South Asian MASH patients will qualify for the 80 mg tier.

Does 80 mg Achieve Adequate Hepatic Exposure?

Population pharmacokinetic modeling from the MAESTRO-NASH program showed that hepatic resmetirom concentrations at 80 mg were sufficient to produce the observed NASH resolution rates in the overall population 4. Whether reduced OATP1B1 function in SLCO1B1 variant carriers diminishes hepatic drug delivery enough to blunt efficacy at 80 mg remains unanswered.

The Endocrine Society's 2023 clinical practice guideline on fatty liver disease does not currently recommend genotype-guided dosing adjustments for resmetirom, partly because the drug was approved after guideline finalization 11. Clinicians should document fibrosis response at 52 weeks via MRE or FibroScan to determine whether treatment goals are being met.

Co-prescribing GLP-1 Receptor Agonists

Many South Asian patients with MASH will already be prescribed a GLP-1 receptor agonist (semaglutide, liraglutide) for type 2 diabetes or obesity. No pharmacokinetic interaction between resmetirom and GLP-1 receptor agonists has been identified, and complementary mechanisms (GLP-1 agents reducing hepatic fat delivery; resmetirom accelerating intrahepatic fatty acid oxidation via THR-beta) may produce additive histological benefit. The ongoing MAESTRO-NASH OUTCOMES trial will provide longer-term safety data that may include combination-therapy arms 12.

A Practical Monitoring Framework for South Asian Patients on Resmetirom

The table below summarizes recommended monitoring intervals for South Asian patients, adapted from the Rezdiffra prescribing label with additional steps warranted by the ethnicity-specific risk factors described in this article.

| Timepoint | Standard Label Requirement | Additional Consideration for South Asian Patients | |---|---|---| | Baseline | ALT, AST, bilirubin; abdominal imaging | TSH, anti-TPO Ab; fasting lipid panel; CK; herbal supplement review; statin dose reconciliation | | 1 month | None specified | CK if statin was dose-adjusted at baseline | | 3 months | ALT, AST | Fasting glucose/HbA1c if new diabetes concern | | 6 months | ALT, AST | Repeat lipid panel; abdominal RUQ ultrasound if biliary symptoms | | 12 months | ALT, AST; consider liver imaging | MRE or FibroScan to assess fibrosis response | | 24 months | Liver biopsy or validated non-invasive test if clinically indicated | Reassess statin dose need and CV risk score |

Pharmacogenomic Testing: Current State and Gaps

PharmGKB currently lists resmetirom as a drug with "limited" pharmacogenomic evidence, meaning the gene-drug pairs have biological plausibility but lack Level 1A clinical annotation 6. The Clinical Pharmacogenetics Implementation Consortium (CPIC) has not issued a guideline for resmetirom as of early 2025.

Routine pre-prescription CYP2C8 or SLCO1B1 genotyping is not standard of care for resmetirom. However, for South Asian patients who are already on statins subject to OATP1B1-mediated interactions, SLCO1B1 genotyping to guide statin selection (already CPIC Level A for simvastatin 13) may indirectly inform the resmetirom co-prescription decision.

The FDA label for Rezdiffra does not include pharmacogenomic labeling, and the drug's NDA pharmacokinetic studies did not stratify by genotype 5. This is a gap that post-marketing pharmacovigilance studies could address.

Evidence Gaps and Research Priorities

Four specific deficiencies limit confident clinical guidance for South Asian patients:

1. No ethnicity-powered subgroup analysis from MAESTRO-NASH or its extension trials.
2. No prospective pharmacokinetic study of resmetirom in SLCO1B1 variant carriers from South Asian ancestry groups.
3. No published data on resmetirom-herbal supplement interactions in this population.
4. No validation of the 80/100 mg weight threshold against MASH severity metrics calibrated for South Asian BMI distributions.

The American Association for the Study of Liver Diseases (AASLD) 2023 practice guidance on MASH pharmacotherapy notes that "clinical trials of MASH therapeutics have historically underenrolled patients of non-European ancestry, limiting the generalizability of efficacy and safety data to diverse populations" 14.

Physicians treating South Asian patients with resmetirom should report adverse events through FDA MedWatch, contributing to the post-marketing dataset that will eventually support ethnicity-specific labeling updates.